Loading
Actym Therapeutics uses a weakened, engineered strain of Salmonella bacteria, given into a vein, to carry immune-activating signals into tumours. Its first medicine, ACTM-838, reached an early trial in advanced solid tumours, which the registry now lists as terminated.
Actym Therapeutics, Inc., of Berkeley, California, developed the STACT (S. Typhimurium-Attenuated Cancer Therapy) platform, an engineered, auxotrophic bacterial vehicle given systemically that accumulates in tumours and is taken up by tumour-resident phagocytic antigen-presenting cells, where it expresses therapeutic payloads. Its lead candidate ACTM-838 delivers an engineered IL-15 superagonist (IL-15plex) and a constitutively active engineered STING. The FDA cleared the IND in May 2024, and a phase 1a/1b dose-escalation study in advanced solid tumours in the United States and Australia (NCT06336148) followed; the ClinicalTrials.gov record shows the study as terminated. The company also lists an undisclosed oncology programme and a fibrosis programme, and its board includes partners from Brandon Capital, Panacea Venture, Illumina Ventures and the Boehringer Ingelheim Venture Fund. Its first registered cancer trial, NCT06336148, was posted on ClinicalTrials.gov in March 2024.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/